Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
BackgroundInfants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim...
Main Authors: | Laurence C. Cheung, Rebecca de Kraa, Joyce Oommen, Grace-Alyssa Chua, Sajla Singh, Anastasia M. Hughes, Emanuela Ferrari, Jette Ford, Sung K. Chiu, Ronald W. Stam, Ursula R. Kees, Sébastien Malinge, Rishi S. Kotecha |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.631594/full |
Similar Items
-
MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia
by: Doralina do Amaral Rabello, et al.
Published: (2018-02-01) -
KMT2A and KMT2B Mediate Memory Function by Affecting Distinct Genomic Regions
by: Cemil Kerimoglu, et al.
Published: (2017-07-01) -
Clinical and Neurobehavioral Features of Three Novel Kabuki Syndrome Patients with Mosaic KMT2D Mutations and a Review of Literature
by: Francesca Romana Lepri, et al.
Published: (2017-12-01) -
KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer
by: Sofia Mastoraki, et al.
Published: (2021-09-01) -
Mature B cell acute lymphoblastic leukaemia with KMT2A-MLLT3 transcripts in children: three case reports and literature reviews
by: Yinghui Cui, et al.
Published: (2021-07-01)